biomed devic servic
major beat-and-rais keep engin hot reiter
top pick rais pt
deliv outstand beat-and-rais highlight remark q/
 increas novaseq sequenc consum continu rate top
pick must stock see fairli clear path
revenu oper margin pleas see mani growth
driver call earlier year come fruition primarili direct-to-consum
genet test popul sequenc project liquid biopsi reiter buy
rais pt rais adj ep estim
massiv beat broad-bas rev y/i crush
y/i /street led beat consum vs model
pull-forward stock order china ahead potenti tariff beat
arrays/servic y/i driven broad-bas growth includ novaseq wg
we liquid biopsi hiseq nextseq adj ep
crush driven revenu margin beat
lift fx adj gm y/i beat adj om
y/i beat
guid us/street expect rev flat slightli
ahead prior expect
moder q/q growth rate consum china order pull forward
demand array meaning q/q lowest year dtc
test growth instrument revenu
rais guid rais revenue guid y/i
midpoint low end
street expect rais adj ep guid
y/i sinc beat low end revenue guid
initi guid street full rais revenue
guid vs prior street expect suggest street math
arrays/servic keep click total services/oth rev y/i beat
microarray consum solid y/i help
microarray servic mostli ancestri
dtc custom agri-genom array services/oth declin q/q
given season weaker vs strong holiday season
novaseq drove rev sequenc instrument
q/q season lighter driven strong convers
novseq hiseq well new-to-high throughput custom reiter
plan place seq unit y/i almost order came
custom new sequenc bench-top system
model rais revenu estim y/i
revenu y/i adj ep
y/i rais revenue growth y/i
adj ep rais revenu estim
adj ep
price close busi juli
domin global leader next
gener sequenc instrument
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
pop seq initi pick steam indic call
genom england complet genom project
track complet sequenc end wrote earlier year
track plan suppli dozen popul sequenc project
world one backyard us-bas us project
initi enrol program start genoytp project
initi includ genotyp sequenc
move clinic applic includ immuno-oncolog
indic recogn revenu continu expect
oncolog program bristol-my squibb bm measur biomark
includ tumor mutat burden tmb seek predict whether patient
respond immunotherapi checkpoint inhibitor intend develop
commerci distribut ivd support bmss oncolog immunotherapi
addit announc mid-april partnership develop commerci
multi-gen panel broad tumor profil result distribut ngs-base
companion diagnost pan-canc indic co-develop partnership
seek approv version trusight tumor companion
diagnost loxo oncolog larotrectinib target ntrk gene fusion
target ret gene alter across tumor type initi
consist object play leadership role enabl sequenc
oncolog applic support routin test immuno-oncolog therapi select
monitor
see robust double-digit growth globe major geograph
region revenu america grew y/i emea grew robust y/i asia
pacif grew y/i shipment greater china includ china taiwan hong
research novaseq convers schedul may
good thing durat growth novaseq adopt like
continu good pace least like longer view
 custom instal least one novaseq fulli convert
fleet instrument novaseq manag cite rational
cadenc clinic translat research activ end result
novaseq like multi-year adopt cycl least like
end longer view depend whether follow
anoth blockbust launch perhap
new custom novaseq manag state
almost novaseq order either new sequenc previous
benchtop custom new-to-illumina custom academ translat
lab clinic test whole exom sequenc we whole genom
sequenc wg convert desktop-onli we wg circul
tumor dna liquid biopsi work methyl analysi rna project
clinic nipt continu grow work harvard pilgrim highlight
data show util average-risk nipt test may facilit broader
commerci payor coverag average-risk nipt view clear grow
adopt average-risk nipt mark materi growth driver next
sever year whenev aet decid cover average-risk women make
birth mother year us hope see perhap
dovish statement acog help bring prenat test much larger
pool women
nextseqdx last novemb launch nextseq second
fda-clear system follow miseqdx system flexibl run either
diagnost mode research mode expect launch number clinic
applic oncolog reproduct health system time earli
custom look use system liquid biopsi test use non-smal cell
lung cancer nsclc addit clinic assay develop
buy unchang target price juli
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
buy unchang target price juli
biomed devic servic
